Is Ketamine Addictive When Used for Depression?

Ketamine has one of the weirdest résumés in modern medicine: it’s been used for decades as an anesthetic, it has a reputation as a party drug,
and now it’s part of a serious conversation about treatment-resistant depression. That mix tends to spark a very reasonable question:
Is ketamine addictive when used for depression?

The honest answer is: ketamine has real abuse potential, but supervised, medical treatment is designed to lower the risk
as much as possible. “Lower risk” doesn’t mean “zero risk,” thoughand the details matter. Let’s break it down in plain English, with the nuance
this topic deserves (and with minimal drama, because your brain already has enough of that).

Important note: This article is for education, not medical advice. Ketamine is a controlled substance. If you’re considering it for depression, talk with a qualified clinician and do not attempt to self-treat.

Ketamine 101: Why It’s Used for Depression at All

Ketamine vs. esketamine (Spravato): not the same thing

When people say “ketamine therapy for depression,” they may be talking about two different treatments:

• Ketamine (often given in clinics as an infusion or other supervised medical route) is
  not FDA-approved for depression. When used for depression, it’s considered off-label.
• Esketamine (brand name Spravato) is a ketamine-derived nasal spray that
  is FDA-approved for certain adult depression indications and is available only through a safety program (more on that soon).

This distinction matters because the safety rules are different. Spravato comes with a structured system for monitoring and limiting misuse.
Off-label ketamine protocols can be responsible and careful toobut standards can vary by clinic.

How ketamine can help depression (the “why is this working so fast?” part)

Traditional antidepressants often target serotonin, norepinephrine, and dopamine, and they can take weeks to show full effects. Ketamine works
differently. It’s known for blocking an NMDA receptor in the brain, which affects glutamate signalingone of the brain’s major “network traffic”
chemicals. Researchers believe this can increase synaptic connectivity and “reboot” stuck mood circuits in some people.

The key word is some. Ketamine isn’t a magic wand. It can bring rapid relief for certain patientsespecially those with
treatment-resistant depressionbut response varies, and it’s usually part of a broader treatment plan (therapy, medications, support systems,
sleep, and so on).

Addiction, Dependence, and Tolerance: Same Neighborhood, Different Houses

Conversations about ketamine get messy because people use “addiction” as a catch-all word. Here’s a cleaner map:

• Tolerance: needing more of a substance over time to get the same effect. Tolerance can happen with many medications,
  even when used as prescribed.
• Physical dependence: your body adapts to a substance, and stopping suddenly may cause withdrawal symptoms.
  This can happen with prescribed drugs (like certain antidepressants or anxiety meds) without someone being “addicted.”
• Addiction (substance use disorder): continued use despite harm, cravings, loss of control, and life disruption.
  This is about behavior and consequencesnot just whether your body adapted.

So when you ask “Is ketamine addictive?” the better question is: does ketamine carry a risk of developing a substance use disorder?
And the answer is yesespecially outside medical supervisionbut the risk is not the same for every context or every person.

So… Is Ketamine Addictive When Used for Depression?

Ketamine has addictive potential because it can produce rewarding effects like euphoria, dissociation, and relief from distress.
It’s also a Schedule III controlled substance in the U.S., which reflects recognized medical use alongside potential for misuse.
But whether a person develops problematic use depends on several factorsespecially how ketamine is used.

Why ketamine can be habit-forming

From a brain-and-behavior standpoint, substances are more likely to be misused when they do at least one of the following:
(1) change consciousness in a noticeable way, (2) relieve emotional pain quickly, (3) create a “reward” feeling people want to repeat, or
(4) become a go-to coping tool. Ketamine can check multiple boxes.

In non-medical settings, people may chase the dissociative “floaty” feeling, the escape, or the numbness. That’s where addiction risk climbs.
In medical depression treatment, the goal is different: symptom reduction under controlled conditions, with monitoring and limits that reduce
the “chasing” dynamic.

Why supervised depression treatment usually lowers (but doesn’t erase) addiction risk

Medical programs reduce risk by building friction into the processyes, the annoying kind. But “annoying” is often what safety looks like:

• On-site administration instead of take-home supply
• Observation and monitoring during and after treatment
• Screening for substance use history and mental health risks
• Documented treatment plans with clear goals and stop points
• Follow-up to evaluate benefit, side effects, and patterns of use

That structure makes it harder to slide into compulsive use. Still, some people can develop psychological cravings or start viewing ketamine as
the only thing standing between them and emotional collapse. That’s not moral failureit’s a sign that the treatment plan needs recalibration.

Who’s at Higher Risk of Misuse or Addiction?

There’s no single “ketamine addiction profile,” but clinicians tend to pay extra attention to risk factors like:

• Past or current substance use disorder (including alcohol or stimulant misuse)
• Strong impulsivity or difficulty with behavioral control
• Using ketamine to escape rather than to treat depression within a plan
• Unsupervised or at-home use (especially with compounded products)
• Frequent dosing without reassessment or “open-ended” treatment with no goals
• Clinic shopping or trying to obtain extra treatments outside the agreed plan

None of these factors automatically disqualify someone from ketamine-based treatment, but they should trigger
more robust screening, tighter monitoring, and a clearer risk-benefit discussion.

What Safe, Medical Ketamine Treatment Usually Looks Like

Spravato has built-in guardrails (the REMS program)

FDA-approved esketamine (Spravato) is only available through a restricted safety program that requires administration in a certified healthcare
setting. Patients are observed after each session, and the medication is not dispensed for home use. This setup exists largely because of known
risks like sedation, dissociation, respiratory depression (reported post-marketing), and abuse/misuse potential.

Off-label ketamine can be careful toobut clinic quality matters

Off-label ketamine for depression is offered in many U.S. clinics, and quality ranges from excellent to “this feels like a spa, but with IVs.”
A responsible clinic typically includes:

• A psychiatric evaluation confirming treatment-resistant depression (not just “I’m having a rough month”)
• Screening for medical contraindications and psychiatric complexity
• Monitoring of vital signs during treatment and a plan for side effects
• Clear documentation of goals, frequency, and reassessment points
• Coordination with ongoing mental health care (therapy, medication management)

Good care is not just “ketamine happens, depression leaves.” It’s a structured process with guardrails and accountability.

Red Flags That Treatment Is Sliding Toward Misuse

Whether ketamine is used for depression or anything else, these signs can suggest the relationship with the drug is becoming unhealthy:

• Craving ketamine between sessions or feeling panicky about not getting it
• Wanting higher or more frequent doses primarily to feel dissociated or “numb,” not to improve depression symptoms
• Hiding use or minimizing it when asked
• Seeking extra treatments from other clinics without telling your main provider
• Using ketamine outside the plan (especially at home)
• Life consequences: money issues, relationship conflict, school/work decline tied to ketamine use

If these show up, it doesn’t automatically mean “addiction.” But it does mean the treatment plan needs to be reviewedquickly and honestly.

Side Effects and Long-Term Safety: What We Know (and What’s Still Unclear)

Short-term effects that are common in supervised treatment

Ketamine and esketamine can cause temporary side effects such as dissociation (feeling detached from self or surroundings), sedation, dizziness,
nausea, and increases in blood pressure. In the case of Spravato, labeling highlights serious risks that require monitoring and observation after
each session.

Long-term concerns (especially with heavy, non-medical use)

A major long-term risk associated with frequent recreational ketamine use is urinary tract and bladder injury, sometimes called
ketamine-induced cystitis. Heavy use has been linked to significant lower urinary tract symptoms and bladder damage. Cognitive and mental health
effects have also been reported with long-term misuse.

For medically supervised depression treatment, the long-term risk picture is still evolving. Many experts emphasize that we need more data on
extended use, optimal maintenance schedules, and how to balance benefits with potential harms over time.

A special caution about at-home compounded ketamine

The FDA has publicly warned about potential risks linked to compounded ketamine products marketed for psychiatric disordersespecially when used
at home without on-site monitoring. Concerns include sedation, dissociation, blood pressure spikes, respiratory depression, psychiatric events,
and abuse/misuse risk. Compounded products also vary in formulation and quality, and they are not FDA-approved for psychiatric indications.

How Clinicians Reduce Addiction Risk (The Boring Stuff That Keeps People Safe)

If you want a simple way to judge safety: responsible providers act like ketamine is powerful. Because it is. Common best practices include:

• Screening for current or past substance misuse
• Baseline and intermittent toxicology testing when clinically appropriate
• Reviewing medication lists and monitoring for risky combinations
• Limiting frequency to the minimum that provides benefit, with regular reassessment
• Tracking symptoms and functioning (not just “Did you feel weird?”)
• Integrating psychotherapy and relapse-prevention strategies for people with higher risk
• Setting exit ramps: clear criteria for pausing, tapering, or stopping treatment

This is the opposite of “infinite refills.” It’s structured care with boundarieswhich is exactly what you want when something has misuse
potential.

Questions to Ask If You’re Considering Ketamine for Depression

If you or a loved one is exploring ketamine-based depression treatment, consider asking:

• What diagnosis and criteria are you using to confirm treatment-resistant depression?
• How do you screen for substance use disorder risk?
• What monitoring happens during and after treatment?
• What’s the treatment plan (goals, frequency, reassessment, stopping rules)?
• How do you coordinate with my therapist/psychiatrist and ongoing depression care?
• Do you offer only in-clinic administration (no take-home ketamine)? If not, why?
• How do you handle side effects like anxiety, dissociation, or blood pressure changes?

If a clinic can’t answer these clearlyor acts offended that you askedconsider that a helpful preview of how they’ll respond if something goes
wrong.

Other Evidence-Based Options for Tough Depression

Ketamine is one tool, not the entire toolbox. For treatment-resistant depression, clinicians may also consider (depending on the person):

• Medication strategies (switching classes, augmentation, combinations)
• Psychotherapy (especially structured approaches like CBT, DBT skills, or trauma-informed therapy when relevant)
• Transcranial magnetic stimulation (TMS)
• Electroconvulsive therapy (ECT), which can be highly effective for severe or refractory cases
• Addressing sleep, substance use, and medical contributors that can worsen depression

In many real-world plans, ketamine-based treatment is paired with psychotherapy and practical supportsbecause mood improves more sustainably
when your environment and coping skills aren’t set to “hard mode.”

The Bottom Line

Yes, ketamine can be addictiveit has recognized abuse potential and can lead to harmful patterns, especially when used
recreationally or without medical oversight. But when ketamine (or esketamine) is used for depression in a structured, supervised setting,
clinics can reduce the risk through screening, monitoring, limited access, and clear treatment goals.

The safest mindset is this: ketamine is not a DIY mental health hack. It’s a powerful medical intervention that should be treated with the same
seriousness you’d want if it were being used on someone you love (including you).

Experiences Related to Ketamine for Depression (A Real-World Look)

People’s experiences with ketamine-based depression treatment tend to fall into a few common themessome encouraging, some uncomfortable, and
some that highlight exactly why addiction risk needs to be taken seriously.

First, many patients describe the timeline as surprising. Traditional antidepressants often feel like waiting for a slow-loading webpage in 2006.
Ketamine, by contrast, can feel like someone finally turned on the lights in a room that’s been dim for a long time. Patients sometimes report a
decrease in suicidal thinking intensity, emotional heaviness, or mental “stuckness” within a day or two after treatment. That rapid relief can be
profoundly meaningfulespecially for people who have tried multiple therapies with limited improvement.

Second, the session experience itself is often described as strange but temporary. Some people feel detached from their body or surroundings,
like they’re watching their thoughts from the audience instead of being shoved onto the stage. Others describe it as dreamlike or “spacey.”
In supervised settings, staff usually prepare patients for this and normalize it: the altered state is expected to peak and then fade. Many
patients say the first session is the most intense, and later ones feel more predictable.

Third, experiences vary widely based on expectations and support. Patients who treat ketamine as part of a broader plantherapy, coping skills,
lifestyle stabilizationoften describe it as a window of opportunity: their mood lifts enough to do the work they previously couldn’t do.
They might finally have the energy to attend therapy consistently, fix sleep habits, or rebuild routines. On the flip side, patients who go in
expecting ketamine to erase depression permanently (like an “unsubscribe” button) can feel crushed if symptoms return. That disappointment can
become a risk factor: chasing the next session for immediate relief, rather than building a sustainable recovery plan.

Fourth, some patients notice psychological pulleven without “getting high.” This is an important point. Addiction isn’t always about partying.
Sometimes it’s about relief. If ketamine becomes the only coping strategy someone trusts, they may start to feel anxious when sessions are spaced
out, or they may push for more frequent treatments even when functional gains are minimal. Clinicians often watch for this pattern and re-center
the plan on measurable outcomes: sleep, daily functioning, mood stability, relationships, school/work performance, and safetynot just how intense
the session felt.

Finally, many people report that responsible clinics feel “structured in a good way.” There’s a check-in, monitoring, a requirement for a ride
home, and an expectation that treatment decisions are made thoughtfully. Patients sometimes joke that the rules are inconvenientno driving, no
rushing out the doorbut later admit those rules made them feel safer. And that’s the goal: ketamine should feel like a medical treatment, not a
product you can binge when life gets hard.

Taken together, real-world experiences underline the main message: ketamine can offer meaningful relief for some people with depression, but the
safest outcomes happen when it’s used with guardrails, follow-up, and honest conversations about risksespecially the risk of turning relief into
dependence.